The study uses several anti-seizure medications administered through a vein, including diazepam, midazolam, lorazepam, propofol, esketamine, lacosamide, levetiracetam, and sodium valproate. These medications are given in a step-by-step approach to stop the seizure activity that is detected by brain wave monitoring.

The research will compare patients who receive seizure treatment with those who do not receive treatment. The main focus is on how well patients recover their ability to function in daily life six months after their cardiac arrest. The study will also look at the cost-effectiveness of the treatment approach.

The purpose of the study is to determine the effectiveness of rapid sedation with Propofol or Midazolam in an intensive care setting compared to intravenous antiseizure treatment in a hospital ward for patients with a specific type of status epilepticus that is resistant to initial treatments. This type of status epilepticus is referred to as non-convulsive status epilepticus, where the seizures are not accompanied by the typical convulsions or shaking. The study will involve monitoring patients over a period to see how well each treatment works in stopping the seizures and to observe any side effects or complications that may arise.

Participants in the study will receive either the antiseizure medications or the sedation medications, and their progress will be closely monitored by medical professionals. The study will assess various outcomes, such as the number of patients whose seizures continue after 24 hours, any new neurological issues that arise, the length of hospital stay, and overall survival rates after treatment. The goal is to find the most effective and safe treatment option for managing this serious condition.

The purpose of the study is to evaluate how effective, safe, and tolerable Ganaxolone is when used alongside standard treatments for RSE. Participants in the study will receive either Ganaxolone or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving Ganaxolone and who is receiving the placebo, to ensure unbiased results.

Throughout the study, participants will be closely monitored to see if their seizures stop within a short time after starting the treatment and to check if there is a need for additional treatments. The study will also look at the safety of Ganaxolone by observing any side effects that may occur. The trial aims to provide valuable information on whether Ganaxolone can be a beneficial addition to the treatment options for people with RSE.

The purpose of the study is to gather evidence on how well these medications can stop the seizures and control epileptic activity within 60 minutes of starting the treatment. Participants in the study will receive either levetiracetam, valproate semisodium, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers know which treatment is being given, to ensure unbiased results.

Throughout the study, participants will be closely monitored to assess the effectiveness of the treatments. The trial will help determine which medication is more effective in managing status epilepticus in the elderly, providing valuable information for future treatment options. The study is expected to continue until November 2026.